Global Targeted Protein Degradation Market Size, Share, Growth Analysis, By Application, By Technology(PROTACs, LYTACs ), By Therapeutic area, By Indication - Industry Forecast 2023-2030

Global Targeted Protein Degradation Market size was valued at USD 103.31 million in 2021 and is poised to grow from USD 113.85 million in 2022 to USD 247.61 million by 2030, growing at a CAGR of 10.2% in the forecast period (2023-2030).

Since it is a relatively recent strategy for medication development and uses tiny compounds to specifically destroy disease-causing proteins, targeted protein degradation is growing in popularity. This method is said to provide a number of benefits over more conventional approaches to drug development. These benefits include unique method of action, potential for combination therapy, broad applicability, improved selectivity, and higher durability. Top-down and bottom-up approaches were used to estimate and validate the size of Targeted Protein Degradation and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

Applications, technologies, therapeutic areas, indications, and geographical regions are used to segment the global market for targeted protein degradation. The market is divided into Small Molecule Drug Discovery, Protein Discovery, Research Applications, and Other End Use Applications. The market has been divided into PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras), SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers), molecular glues, and other categories based on technology. The market is divided into oncology, immunology, genetic disorders, and other diseases based on therapeutic area. According to preliminary data, the market is divided into categories for solid tumors, leukemia, breast cancer, and lung cancer. North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America are the different geographic segments of the market.

Driver

Increasing Demand for Effective Cancer Treatment to Boost Market Growth

The growing demand for more efficient treatments for a number of disorders is one of the reasons propelling the market for targeted protein degradation. There is a rising demand for medicines that can address the underlying causes of diseases like cancer, genetic abnormalities, and autoimmune diseases because they have a substantial influence on patients' health and quality of life. The potential for preferentially focusing on disease-causing proteins through targeted protein breakdown could lead to more effective treatments with fewer adverse effects. This strategy makes it possible to create medications that selectively attack the pathogen-causing proteins while protecting healthy cells and tissues.

Restraints

Complexity of Targeted Protein Degradation to Hinder Market Growth

The complexity of this industry is one of the main obstacles facing the targeted protein degradation market. This strategy necessitates a thorough knowledge of the structure and purpose of proteins in addition to sophisticated skills in drug research and design. This technique can make it difficult and time-consuming to develop novel therapeutics, which could impede the field's advancement. Developing medications that can selectively degrade particular proteins within cells is a relatively new and complicated field known as targeted protein degradation. These medications are made to benefit from the cell's built-in machinery for protein breakdown, which enables them to specifically target disease-causing proteins while sparing healthy cells.

Market Trend

The increased focus on oral medication development is one of the market's major developments in targeted protein degradation. The rising need for more patient-friendly medicines that provide better convenience and compliance is what is driving this development. Because they may be conveniently administered at home and don't require patients to travel to hospitals or clinics for treatment, oral medications offer a substantial benefit over other drug delivery methods like injections and infusions. Several pharmaceutical companies are making significant investments in the research and development of oral medications for targeted protein breakdown to counter this tendency. Drugs that can make it past the digestive system and into the body's target organs are being developed.